Canada Pension Plan Investment Board Buys Shares of 52,834 Medpace Holdings, Inc. $MEDP

Canada Pension Plan Investment Board purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 52,834 shares of the company’s stock, valued at approximately $27,980,000.

Other institutional investors also recently modified their holdings of the company. Johnson Financial Group Inc. acquired a new stake in Medpace in the second quarter valued at about $27,000. Elyxium Wealth LLC acquired a new position in Medpace during the fourth quarter worth about $30,000. Jones Financial Companies Lllp acquired a new position in Medpace during the second quarter worth about $30,000. Allied Private Wealth LLC bought a new position in shares of Medpace in the second quarter worth about $31,000. Finally, Kilter Group LLC bought a new position in shares of Medpace in the second quarter worth about $31,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on MEDP. Barclays set a $600.00 price target on shares of Medpace in a report on Thursday, July 23rd. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Robert W. Baird raised their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. TD Cowen boosted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Finally, Mizuho upped their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $584.18.

Medpace Price Performance

Medpace stock opened at $600.65 on Friday. The business has a 50 day moving average of $565.33 and a 200-day moving average of $494.55. The company has a market capitalization of $16.76 billion, a P/E ratio of 35.21, a P/E/G ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same period last year, the company earned $3.10 EPS. The firm’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insider Buying and Selling at Medpace

In related news, Director Brian T. Carley sold 5,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the sale, the director directly owned 27,825 shares in the company, valued at $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the transaction, the director directly owned 3,798 shares of the company’s stock, valued at approximately $2,302,157.70. This represents a 65.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 133,821 shares of company stock worth $81,748,135 over the last ninety days. Insiders own 20.50% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.